Enzo Biochem, Inc.  

(Public, NYSE:ENZ)   Watch this stock  
Find more results for ENZ
+0.08 (1.22%)
Feb 24 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 6.51 - 6.67
52 week 4.00 - 7.51
Open 6.54
Vol / Avg. 0.00/143,490.00
Mkt cap 312.04M
P/E 7.93
Div/yield     -
EPS 0.84
Shares 46.29M
Beta 1.40
Inst. own 63%
Mar 7, 2017
Q2 2017 Enzo Biochem Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 9, 2016
Q1 2017 Enzo Biochem Inc Earnings Call
Dec 8, 2016
Q1 2017 Enzo Biochem Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Oct '16) 2016
Net profit margin -5.61% 44.06%
Operating margin -4.79% 45.73%
EBITD margin - -0.02%
Return on average assets -5.32% 50.26%
Return on average equity -6.64% 68.53%
Employees 446 -
CDP Score - -


United States - Map
+1-516-7555500 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company's segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women's health infectious agents, as well as for use in the identification of pathogens for other markets.

Officers and directors

Barry W. Weiner President, Chief Financial Officer, Principal Accounting Officer, Treasurer, Director
Age: 65
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Elazar Rabbani Ph.D. Chairman of the Board, Chief Executive Officer, Secretary
Age: 72
Bio & Compensation  - Reuters
James M. O'Brien Executive Vice President - Finance
Age: 49
Bio & Compensation  - Reuters
David C. Goldberg Vice President - Corporate Development, General Manager of Enzo Clinical Labs
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Dieter Schapfel M.D. Chief Medical Director
Age: 52
Bio & Compensation  - Reuters
Bruce A. Hanna Ph.D. Director
Bio & Compensation  - Reuters
Gregory M. Bortz Independent Director
Age: 46
Bio & Compensation  - Reuters
Dov Perlysky Independent Director
Age: 53
Bio & Compensation  - Reuters